Jason Wellen

Medicine & Life Sciences

1. Allografts 30%
2. Antibodies 14%
3. Antiviral Agents 10%
4. Autoantigens 21%
5. Biopsy 7%
6. Body Mass Index 11%
7. Calcineurin Inhibitors 8%
8. Cohort Studies 14%
9. Collagen 7%
10. Common Hepatic Duct 6%
11. Costs and Cost Analysis 13%
12. Delayed Graft Function 10%
13. End Stage Liver Disease 8%
14. Everolimus 13%
15. Fibronectins 8%
16. Graft Survival 27%
17. Hepacivirus 11%
18. Hepatitis B Antibodies 6%
19. Hepatitis C 11%
20. Hepatocellular Carcinoma 8%
21. HLA Antigens 9%
22. Immunoglobulin Class Switching 7%
23. Incisional Hernia 8%
24. Kidney 46%
25. Kidney Transplantation 80%
26. Learning Curve 7%
27. Liver 9%
28. Liver Transplantation 73%
29. Living Donors 37%
30. Morbid Obesity 12%
31. Nephrectomy 15%
32. Operating Rooms 14%
33. Organ Transplantation 14%
34. Organizations 10%
35. Pancreas 29%
36. Pancreas Transplantation 27%
37. Pediatrics 11%
38. Psychology Rejection 6%
39. Retrospective Studies 7%
40. Robotics 12%
41. Survival 19%
42. Taxes 8%
43. Tissue and Organ Procurement 37%
44. Tissue Donors 100%
45. TOR Serine-Threonine Kinases 11%
46. Transplant Recipients 27%
47. Transplantation 16%
48. Transplants 83%
49. Type 1 Diabetes Mellitus 9%
50. Warm Ischemia 6%